StreetInsider.com News Articles

Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry

Wed, 09 Sep 2026 08:30:00 -0400

Complementary Technologies Deliver an Integrated, End-to-End Clinical Flow Cytometry Workflow for Laboratories Across Europe

FREMONT, Calif., and HAMBURG, Germany, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sysmex Europe SE, a leader in diagnostic and healthcare solutions, and Cytek Biosciences, Inc. (Nasdaq: CTKB), a leader in spectral flow cytometry technology, today announced a strategic collaboration across over a dozen European countries to enhance clinical flow cytometry workflows and expand access to innovative diagnostic solutions.

The collaboration brings together the expertise and technologies of both companies to provide clinical laboratories with a broader

Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry

Wed, 09 Sep 2026 08:30:00 -0400

Complementary Technologies Deliver an Integrated, End-to-End Clinical Flow Cytometry Workflow for Laboratories Across Europe

The collaboration brings together the expertise and technologies of both companies to provide clinical laboratories with a broader

Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

Thu, 03 Sep 2026 17:00:00 -0400

FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41^st Annual International Clinical Cytometry Meeting & Course.

Set apart from traditional flow cytometry approaches, Cytek’s distinctive Full Spectrum Profiling™ (FSP^®) technology is helping to expand

Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

Thu, 03 Sep 2026 17:00:00 -0400

Set apart from traditional flow cytometry approaches, Cytek’s distinctive Full Spectrum Profiling™ (FSP^®) technology is helping to expand

Form 8-K Cytek Biosciences, Inc. For: Aug 21

Mon, 24 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26963757.html

Form 8-K Cytek Biosciences, Inc. For: Aug 21

Mon, 24 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26963757.html

Cytek faces $56M damages award in Beckman Coulter patent case

Fri, 21 Aug 2026 16:37:20 -0400

Cytek Biosciences (Nasdaq: CTKB) announced that a jury in the U.S. District Court for the District of Delaware returned a verdict in a patent infringement case brought by Beckman Coulter, Inc., finding in Cytek's favor on three of four asserted patent claims.

The jury found noninfringement and invalidity on three claims, but found infringement under the doctrine of equivalents on one claim. The jury awarded past damages of $20 million in lost profits and $36 million in royalties, totaling $56 million.

Cytek said it intends to pursue post-verdict motions challenging the infringement finding under the doctrine of equivalents and the related damages

Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding